Science and Innovations in MedicineScience and Innovations in MedicineНаука и инновации в медицине2500-13882618-754XFSBEI of Higher Education SamSMU of Ministry of Health of the Russian Federation4373910.35693/2500-1388-2019-4-1-20-25CardiologyКардиологияResearch ArticleRisk factors in patients with familial hypercholesterolemia: risk stratification and treatment tacticsВклад факторов риска в стратификацию риска пациентов с семейной гиперхолестеринемией и тактику их леченияhttps://orcid.org/0000-0003-4391-6687SimerzinVasilii VasilievichСимерзинВасилий Васильевич
Russian Federation

PhD, Professor of the Faculty Therapy Department, SamSMU

д.м.н., профессор кафедры факультетской терапии СамГМУ

simerzi@mail.ruhttps://orcid.org/0000-0001-7492-8045KrasovskayaMargarita A.КрасовскаяМ. А.
Russian Federation

general practitioner in Clinics of SamSMU

врач-терапевт клиники факультетской терапии СамГМУ

geliosmax@yandex.ruGagloevAnton V.ГаглоевА. В.
Russian Federation

student Samara State Medical University

студент группы научно-педагогического резерва СамГМУ

anton-gaglo@yandex.ruSamara State Medical UniversityФГБОУ ВО «Самарский государственный медицинский университет» Минздрава России1503201941VOL 4, NO1 (2019)ТОМ 4, №1 (2019)202508092020Copyright ©; 2019, Simerzin V.V., Krasovskaya M.A., Gagloev A.V.Copyright ©; 2019, Симерзин В.В., Красовская М.А., Гаглоев А.В.2019Simerzin V.V., Krasovskaya M.A., Gagloev A.V.Симерзин В.В., Красовская М.А., Гаглоев А.В.https://creativecommons.org/licenses/by/4.0https://innoscience.ru/2500-1388/article/view/43739

This review focuses on traditional and occasional risk factors in patients with familial hypercholesterolemia (FH) that influence their medical condition along with the level of the extreme hypercholesterolemia and their age (time of exposure to hypercholesterolemia).

The risk factors in question can define the patients' stratification in groups of high and extreme risk, assist in treatment tactics and strategy.

В обзорной статье отмечено, что клиническое состояние пациентов с семейной гиперхолестеринемией и его прогноз определяется не только уровнем самой экстремальной гиперхолестеринемии, возрастом (временем экспозиции ГХС), но и наличием других традиционных и дополнительных факторов риска.

Учет этих факторов позволяет проводить риск-страти-фикацию пациентов с выделением групп высокого и очень высокого риска, а также дает возможность намечать стратегию и тактику их ведения.

risk factorsfamilial hyperchole-sterolemiarisk stratificationфакторы рискасемейная гиперхолестеринемиястратификация рискаFerence BA, Ginsberg HN, Graham I at al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017 Aug 21;38(32):2459–2472. doi: 10.1093/eurheartj/ehx144Prospective Studies Collaboration. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55000 vascular deaths. Lancet. 2007;370:1829–1839.NICE clinical guidelines 71. Identification and management of familial hypercholesterolemia. Issue date: August 2008. Available from: URL: http://www.nice.org.uk/nicemedia/live/12048/41697/41697.pdf. Accessed Mar 2013.Fernandez-Friera L, Fuster V, Lpez-Melgar B et al. Normal LDL-Cholesterol Levels Are Associated With Subclinical Atherosclerosis in the Absence of Risk Factors. Journal of the American College of Cardiology, 70(24):2979–2991. doi: https://doi.org/10.1016/j.jacc.2017.10.024Huijgen R, Hutten BA, Kindt I et al. Discriminative ability of LDL-cholesterol to identify patients with familial hypercholesterolemia: a crosssectional study in 26,406 individuals tested for genetic FH. Circ Cardiovasc Genet. 2012;5:354–359.Starr B, Hadfield SG, Hutten BA et al. Development of sensitive and specific age- and gender-specific lowdensity lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing. Clin Chem Lab Med. 2008;46:791–803.Peura P, Martikainen J, Soini E at al. Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men. Curr Med Res Opin 2008;24:1823–1832.Oosterveer DM, Versmissen J, Schinkel AF et al. Clinical and genetic factors influencing cardiovascular risk in patients with familial hypercholesterolemia. Clin Lipidol. 2010;5:189–97.Nordestgaard BG, Chapman MJ, Humphries SE et al. European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population:guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013 Dec;34(45):3478–90a.Chapman MJ, Ginsberg HN, Amarenco P et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011;32:1345–1361.Perk J, De BG, Gohlke H, Graham I at al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Atherosclerosis. 2012;223:1–68.Watts GF, Sullivan DR, Poplawski N at al. Familial hypercholesterolaemia: a model of care for Australasia. Atheroscler Suppl. 2011;12:221–263.Claassen L, Henneman L, Kindt I et al. Perceived risk and representations of cardiovascular disease and preventive behaviour in people diagnosed with familial hypercholesterolemia. J Health Psychol. 2010;15:33–43.Slack J. Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states. Lancet. 1969. Dec 27;2(7635):1380–2.Hopkins PN, Toth PP, Ballantyne CM, Rader DJ. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011 Jun;5(3):S9–17.Widhalm K, Dirisamer A, Lindemayr A. Diagnosis of families with familial hypercholesterolaemia and/or Apo B-100 defect by means of DNA analysis of LDL-receptor gene mutations. J Inherit Metab Dis. 2007 Apr;30(2):239–47.Ежов М.В., Сергиенко И.В., Рожкова Т.А. и др. Российские рекомендации по диагностике и лечению семейной гиперхолестеринемии. Атеросклероз и дислипидемии. 2016;4:21–9. [Ezhov MV, Sergienko IV, Rozhkova TA at al. Russian recommendations for the diagnosis and treatment of familial hypercholesterolemia. Ateroskleroz i dislipidemii. 2016;4:21–9. (In Russ.)].Piepoli MF, Hoes AW, Agewall S at al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016 Aug 1;37(29):2315–81.Ежов М.В., Сергиенко И.В., Аронов Д.М. и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации VI пересмотр. Атеросклероз и дислипидемии. 2017;3:5–22. [Ezhov MV, Sergienko IV, Aronov DM at al. Diagnosis and correction of lipid metabolism disorders in order to prevent and treat atherosclerosis. Russian recommendations VI revision. Ateroskleroz i dislipidemii. 2017;3:5–22. (In Russ.)].Familial hypercholesterolaemia: identification and management. NICE guideline, 2008 https://www.nice.org.uk/guidance/cg71/resources/familial-hypercholesterolaemia-identification-and-management-pdf-975623384005Vuorio A, Doherty KF, Humphries SE at al. Statin treatment of children with familial hypercholesterolemia – trying to balance incomplete evidence of long-term safety and clinical accountability: are we approaching a consensus? Atherosclerosis. 2013;226:315–20.Harada-Shiba M, Arai H, Oikawa S at al. Guidelines for the management of familial hypercholesterolemia. J Atheroscler Thromb. 2012;19(12):1043-60. Epub 2012 Oct 25.Catapano AL, Graham I, De Backer G at al. Authors/Task Force Members; Additional Contributor. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016 Oct 14;37(39):2999–3058.Greenland P, Alpert JS, Beller GA at al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2010 Dec 21;122(25):e584–636. doi: 10.1161/CIR.0b013e3182051b4cEngelen L, Ferreira I, Stehouwer CD at al. Reference Values for Arterial Measurements Collaboration. Reference intervals for common carotid intima-media thickness measured with echotracking: relation with risk factors. Eur Heart J. 2013;34:2368–2380. doi: 10.1093/eurheartj/ehs380Кухарчук В.В., Малышев П.П., Мешков А.Н. Семейная гиперхолестеринемия: Современные аспекты диагностики, профилактики и терапии. Кардиология. 2009;1:76–83. [Kukharchuk VV, Malyshev PP, Meshkov AN. Familial hypercholesterolemia: modern aspects of diagnosis, prevention and therapy. Kardiologiya. 2009;1:76-83. (In Russ.)].Thanassoulis G, Campbell CY, Owens DS at al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med. 2013;368:503–512.Montalescot G, Sechtem U, Achenbach S at al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013 Oct;34(38):2949–3003. doi: 10.1093/eurheartj/eht296Stone NJ, Robinson JG, Lichtenstein AH at al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;129:S1–S45. doi: 10.1161/01.cir.0000437738.63853.7aCannon CP., Blazing MA., Giugliano RP et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015; 372:2387–2397. doi: 10.1056/NEJMoa1410489Raymond C, Cho L, Rocco M, . Hazen SL. New cholesterol guidelines: Worth the wait? Cleveland Clinic Journal of Medicine. 2014 January;81(1):11–19.Baigent C, Keech A, Kearney PM at al. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005 Oct 8;366(9493):1267–78. doi: 10.1016/S0140-6736(05)67394-1Boekholdt SM, Hovingh GK, Mora S at al. Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events A Meta-Analysis of Statin Trials. Journal of the American College of Cardiology. 2014; 64:485-494. doi: 10.1016/j.jacc.2014.02.615Van Himbergen TM, Matthan NR, Resteghini NA at al. Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers. J Lipid Res. 2009;50:730–739.Mayne J, Dewpura T, Raymond A, Cousins M at al. Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. Lipids Health Dis. 2008 Jun 11;7:22. doi: 10.1186/1476-511X-7-22Awan Z, Seidah NG, MacFadyen JG at al. Rosuvastatin, Proprotein Convertase Subtilisin/Kexin Type 9 Concentrations, and LDL Cholesterol Response: the JUPITER Trial. Clinical Chemistry, 58(1):183–189. doi: 10.1373/clinchem.2011.172932Jones PH, Nair R, Thakker KM. Prevalence of Dyslipidemia and Lipid Goal Attainment in Statin-Treated Subjects From 3 Data Sources: A Retrospective Analysis. J Am Heart Assoc. 2012 Dec; 1(6): e001800. doi: 10.1161/JAHA.112.001800Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol. 2012 May–Jun;6(3):208–15. doi: 10.1016/j.jacl.2012.03.003Pijlman AH, Huijgen R, Verhagen SN at al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. Atherosclerosis. 2010 Mar;209(1):189–94. doi: 10.1016/j.atherosclerosis.2009.09.014Kastelein JJ, Robinson JG, Farnier M at al. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies. Cardiovasc Drugs Ther. 2014 Jun;28(3):281–9. doi: 10.1007/s10557-014-6523-zColhoun HM, Robinson JG, Farnier M et al. Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials. BMC Cardiovascular Disorders. 2014;14:121. doi: 10.1186/1471-2261-14-121Schwartz GG, Bessac L, Berdan LG, Bhatt DL at al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J. 2014 Nov;168(5):682–9. doi: 10.1016/j.ahj.2014.07.028Landmesser M. Chapman J, Jane K et al. 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia Ulf. European Heart Journal. 2017;10:1–13. doi: 10.1093/eurheartj/ehx549